OLMA NASDAQ
Olema Pharmaceuticals, Inc.
1W: -2.9%
1M: -18.2%
3M: -37.1%
YTD: -72.2%
1Y: -12.3%
3Y: -33.5%
5Y: -73.7%
$7.04
+0.42 (+6.34%)
Pre-Market: $7.15 (+0.11, +1.56%)
Weekly Expected Move ±7.9%
$5
$6
$6
$7
$7
Credit Risk of going bust: lower than 55% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Olema Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $660K against a stock market value of $616.0M.
Distance to default 5.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $660K (short-term plus half of long-term), stock volatility 112.1%; Altman Z'' 6.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Olema Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $660K against a stock market value of $616.0M.
Distance to default 5.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $660K (short-term plus half of long-term), stock volatility 112.1%; Altman Z'' 6.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-06-09
Earliest Filing
2024-12-02
Latest Filing
partner: 4
investor: 1
Counterparties (Filed by OLMA)
5 relationshipsCompanies named in OLMA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Novartis Pharma AG | NVSEF | partner | Clinical Trial Collaboration and Supply Agreement for ribociclib supply and joint R&D | 2024-12-02 | View |
| BVF Partners L.P. | — | investor | Institutional investor and holder of more than 5% of outstanding capital stock | 2024-12-02 | View |
| Cowen and Company, LLC | — | partner | Sales agent for the 'At the Market' Equity Offering Program | 2024-01-05 | View |
| Oppenheimer & Co., Inc. | OPY | partner | Prior sales agent for the terminated 'At the Market' Equity Offering Program | 2024-01-05 | View |
| Aurigene Discovery Technologies Limited | — | partner | Exclusive global license agreement for oncology target research and development | 2022-06-09 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-15 | Officer/Director Change | View | |
| 2026-08-13 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Shareholder Vote | View | |
| 2026-05-26 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-05-01 | Material Agreement; Financial Obligation | Agreement | View |
| 2026-04-29 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-18 | Other Events | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-02 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR